Here are 1-3 brief analogies for BNB Plus (BNBX):

• Think of it as Verisign for physical products, using DNA markers to authenticate goods and secure supply chains.
• Like a specialized LabCorp or Charles River Labs, developing advanced DNA/RNA diagnostics and therapeutic solutions.

• SigNature molecular tags: DNA-based tags used for supply chain security, anti-counterfeiting, and anti-theft applications.
• SigNify IF portable DNA readers: Devices that provide real-time authentication of molecular tags in the field.
• SigNify consumable reagent test kits: Kits designed to be used with SigNify readers for real-time authentication of molecular tags.
• CertainT platform: A system of tagging, testing, and tracking solutions that enables manufacturers and brands to provide proof of their product claims.
• LineaTM COVID-19 Assay Kit: A PCR-based molecular diagnostic test kit developed for COVID-19 detection.
• safeCircle COVID-19 diagnostic test kit: A diagnostic test kit aimed at preventing virus spread within communities, schools, or workplaces.
• Preclinical contract research and manufacturing services: Services offered for nucleic acid-based therapeutic markets.
• Contract research services for RNA based drug and biologic customers: Research services provided for preclinical studies involving RNA-based drugs and biologics.
• Invasive circulating tumor cell capture and identification technology: A patented functional assay technology designed to capture and identify live invasive circulating tumor cells and associated lymphocytes.

BNB Plus (symbol: BNBX) sells primarily to other companies and institutions. Based on the provided description of the company (Applied DNA Sciences, Inc.), its major customers fall into the following categories:

• Pharmaceutical and Biotechnology Companies: These customers utilize BNB Plus's DNA-based technology solutions for nucleic acid-based in vitro diagnostics, preclinical nucleic acid-based drug development and manufacturing, and contract research services for RNA-based drugs and biologics.
• Manufacturers, Brands, and Trade Organizations: These entities use BNB Plus's supply chain security, anti-counterfeiting, and anti-theft technology solutions, including SigNature molecular tags, SigNify IF portable DNA readers, and the CertainT platform, to fortify brand protection, strengthen supply chain security, and authenticate product claims.
• Healthcare Providers and Institutions: This category includes organizations such as hospitals, diagnostic laboratories, schools, and workplaces that purchase COVID-19 PCR-based molecular diagnostic test kits (LineaTM COVID-19 Assay Kit and safeCircle) to prevent virus spread and for diagnostic purposes.

Clay Shorrock, Esq. President and Chief Executive Officer

Mr. Shorrock was appointed President and Chief Executive Officer in September 2025, following the company's pivot to a digital asset treasury strategy centered on BNB. He previously served as Chief Legal Officer and Executive Director of Business Development from April 2021 to September 2025, and as President of LineaRx, the company's biotherapeutics subsidiary, from December 2024 to September 2025. During his tenure, Mr. Shorrock led the company's legal, regulatory, risk mitigation, intellectual property, and business development functions and was instrumental in developing the LineaDNA and LineaIVT platforms. Prior to rejoining the company in 2021, he practiced in intellectual property groups at Lowndes, Drosdick, Doster, Kantor & Reed, P.A. and Allen, Dyer, Doppelt & Gilchrist, P.A.

Beth Jantzen Chief Financial Officer

Ms. Jantzen has served as Chief Financial Officer since February 2015, after joining Applied DNA Sciences as Controller in 2013. Before her time at the company, she was a senior manager at Marcum LLP from 2000 to 2013, where she specialized in SEC reporting and Sarbanes-Oxley compliance. Ms. Jantzen is a Certified Public Accountant and holds a B.S. in Accounting from Binghamton University (SUNY).

Judy Murrah Chairperson of the Board

Ms. Murrah was appointed Chairperson of the Board in June 2025 and Strategic Transition Advisor in September 2025, concurrent with the company's pivot to a digital asset treasury strategy focused on BNB. She joined Applied DNA Sciences in 2013 as Chief Information Officer, was appointed Corporate Secretary in 2017, Chief Operating Officer in 2021, and President in December 2024, and CEO in June 2025. Before joining Applied DNA, Ms. Murrah held leadership roles at Symbol Technologies, contributing to its growth to approximately $2 billion in revenue, and later at Motorola following its acquisition of Symbol. She is credited as an inventor on 14 U.S. patents and holds an MBA from Harvard Business School.

Patrick Horsman, CFA Chief Investment Officer

Mr. Horsman was appointed Chief Investment Officer of BNB Plus in October 2025.

Joseph Ceccoli Board Member

Mr. Ceccoli has served as a Board member since December 2014. He is the Founder, President, and CEO of Biocogent, LLC, a bioscience company he started in 2010 that focuses on developing and commercializing skin-active molecules and treatment products.

1. Exposure to Cryptocurrency Market Volatility and Regulatory Uncertainty: The most significant new risk for BNB Plus (BNBX) stems from its recently adopted digital asset treasury strategy, which is centered on BNB, a cryptocurrency. This strategy exposes the company to the extreme price volatility inherent in the cryptocurrency market, which can lead to significant fluctuations in its asset value and financial performance. Furthermore, the global regulatory landscape for digital assets is still developing and is subject to rapid changes, which could adversely affect the company's ability to manage its BNB treasury, utilize the Binance ecosystem, or even the value and liquidity of BNB itself.

2. Dependence on Market Adoption and Competition in Specialized Biotechnology Markets: Despite its new digital asset focus, BNB Plus maintains its core biotechnology operations, which involve developing and marketing DNA-based technology solutions for nucleic acid-based diagnostics, drug development, and supply chain security. The success of these solutions is highly dependent on achieving broad market acceptance and effectively competing against existing and emerging technologies and solutions offered by other companies. Failure to gain sufficient market traction or to differentiate its offerings in these highly specialized and competitive fields poses a substantial risk to the revenue and profitability of this segment of the business.

3. Intellectual Property Risks: The company's biotechnology segment relies heavily on proprietary DNA-based technologies. The ability to maintain and protect its intellectual property, including patents, trade secrets, and trademarks, is critical for its competitive advantage. Risks include the potential for intellectual property infringement by third parties, challenges to the validity or enforceability of its patents, or the inability to secure new patents for future innovations, which could negatively impact its ability to commercialize its biotech solutions.

The following are clear emerging threats for BNB Plus (symbol: BNBX), which operates as Applied DNA Sciences, Inc.:

1. Waning Demand and Shift in COVID-19 Testing Modalities: The significant and ongoing decline in demand for PCR-based molecular diagnostic tests for COVID-19. This decline is driven by the widespread availability and adoption of rapid at-home antigen tests, reduced public health mandates for mass testing, and a general decrease in the urgency of COVID-19 screening. This market shift directly threatens the revenue streams from Applied DNA Sciences' LineaTM COVID-19 Assay Kit and safeCircle products, as the market moves towards different, often more convenient or cost-effective, diagnostic approaches.
2. Emergence of Advanced Alternative Anti-Counterfeiting and Supply Chain Security Technologies: The continuous development and increasing adoption of non-DNA-based anti-counterfeiting and supply chain traceability solutions. These include advanced blockchain-enabled platforms for immutable record-keeping, sophisticated quantum dot tagging, next-generation secure RFID technologies, or other novel physical and digital authentication methods. Should these alternatives prove to be more cost-effective, scalable, easier to integrate, or offer superior features compared to Applied DNA Sciences' DNA-based molecular tags (SigNature) and authentication platforms (CertainT), they could significantly displace demand for the company's core security products.

BNB Plus (symbol: BNBX) operates in several addressable markets, encompassing both digital asset treasury services and biotechnology solutions. Based on recent market analyses, the addressable markets for its main products and services are as follows:

Digital Asset Treasury and Decentralized Finance

• The global Decentralized Finance (DeFi) market, a relevant segment for BNB Plus's digital asset treasury strategy, was valued at over USD 237 billion in Total Value Locked (TVL) in Q3 2025. This market is projected to grow significantly, with estimates ranging from USD 770.56 billion by 2031 to USD 1,078.5 billion by 2035. Institutional investment in crypto, including through exchange-traded funds (ETFs), is a key driver, with Bitcoin ETF holdings by institutional investors exceeding USD 33 billion by the end of 2024. The total market capitalization of digital asset treasuries (DATs) reached approximately USD 150 billion in September 2025.

Biotechnology Solutions

DNA Manufacturing (including Synthetic DNA and Cell-Free DNA)

• The global DNA manufacturing market is estimated at USD 7.56 billion in 2026 and is expected to reach USD 23.24 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 17.4%. Within this, synthetic DNA is projected to hold a 50.2% share in 2026. Other reports indicate the global DNA manufacturing market size was approximately USD 5.65 billion in 2024 and is projected to reach USD 14.96 billion by 2030, with a CAGR of 18.10%, or USD 21.82 billion by 2034 with a CAGR of 14.62%. North America accounted for 47.38% of the global revenue in 2024. The global DNA synthesis market, a related segment, is calculated at USD 6.37 billion in 2026 and projected to reach USD 27.03 billion by 2035.

mRNA Synthesis and Manufacturing

• The global mRNA synthesis and manufacturing market size was estimated at USD 3.19 billion in 2025 and is predicted to increase to approximately USD 5.64 billion by 2035, at a CAGR of 5.85%. Other estimates for this market vary, including a valuation of USD 1.58 billion in 2025, projected to reach USD 1.87 billion by 2034, or a valuation of USD 56.7 billion in 2026, reaching USD 67.4 billion by 2033. North America holds a significant share, with one report indicating approximately 42.6% in 2025.

Molecular Diagnostics (including PCR-based tests)

• The global molecular diagnostics market size was calculated at USD 45.11 billion in 2025 and is predicted to reach approximately USD 66.34 billion by 2035. North America held the highest revenue share of over 40% in 2025. Other reports estimate the global market at USD 27 billion in 2024, growing to USD 40.4 billion by 2034, or USD 18.85 billion in 2025, reaching USD 25.59 billion by 2033. The global RT PCR test kits market size was USD 4.13 billion in 2024 and is expected to reach USD 6.41 billion by 2031. North America held more than 40% of the global RT PCR test kits market revenue in 2024.

Supply Chain Security, Anti-Counterfeiting, and Anti-Theft

• The global anti-counterfeit packaging technologies market was valued at USD 173.06 billion in 2025 and is anticipated to reach USD 533.19 billion by 2035, with a CAGR of 11.91%. North America leads this market with a 38.82% share. Other sources similarly project the global anti-counterfeit packaging market to be valued around USD 200.2 billion in 2025, growing to USD 561.5 billion by 2034, or USD 204.08 billion in 2025, reaching USD 428.28 billion by 2033. North America consistently holds the largest share in this market, with estimates ranging from 43.21% in 2025 to 51.9% in 2025.

Here are 3-5 expected drivers of future revenue growth for BNB Plus (symbol: BNBX) over the next 2-3 years:

1. Digital Asset Treasury Strategy Centered on BNB: A significant driver of future revenue growth is the company's new strategic focus on a yield-oriented BNB digital asset treasury. BNB Plus aims to optimize yield generation and token accumulation within the Binance ecosystem, which could generate revenue through various DeFi-focused strategies and the appreciation of its BNB token holdings. This strategy is a key aspect of the company's rebranding and new ticker symbol.
2. Expansion of Nucleic Acid Production Technologies: The company continues to commercialize its proprietary LineaDNA platform and other nucleic acid production solutions for biopharmaceutical and diagnostics applications. This includes the enzymatic manufacture of synthetic DNA for use in nucleic acid-based therapeutics and the development and sale of its proprietary RNA Polymerase (RNAP) for mRNA therapeutics. Growth in these areas will be driven by increased demand from the biotechnology and biopharmaceutical sectors.
3. Growth in Therapeutic DNA Production Services: This segment specifically focuses on the enzymatic manufacture of synthetic DNA for nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in mRNA therapeutics. As the market for advanced therapeutics, particularly gene and cell therapies and mRNA vaccines, continues to expand, the demand for BNB Plus's specialized production services is expected to increase, contributing to revenue growth.